Skip to main navigation Skip to search Skip to main content

Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

  • on behalf of the REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]
  • Division of Gastroenterology
  • Rabin Medical Center Israel
  • Tel Aviv University
  • Technion-Israel Institute of Technology
  • Shaare Zedek Medical Center
  • Hebrew University of Jerusalem
  • Clalit Health Services
  • Ariel University
  • Holon Institute of Technology
  • Sheba Medical Center at Tel Hashomer

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases'. Together they form a unique fingerprint.
Sort by

Keyphrases

Immunology and Microbiology